T2 Biosystems, Inc.
TTOO
$0.1255
-$0.006-4.56%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.99M | 1.95M | 2.06M | 1.68M | 1.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.99M | 1.95M | 2.06M | 1.68M | 1.47M |
| Cost of Revenue | 6.75M | 6.05M | 7.92M | 5.74M | 6.48M |
| Gross Profit | -4.76M | -4.10M | -5.86M | -4.06M | -5.01M |
| SG&A Expenses | 5.38M | 5.47M | 6.74M | 5.26M | 5.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.15M | 11.53M | 14.66M | 11.00M | 12.57M |
| Operating Income | -10.16M | -9.58M | -12.60M | -9.32M | -11.10M |
| Income Before Tax | -10.12M | -8.96M | -13.53M | -10.34M | -15.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.12M | -8.96M | -13.53M | -10.34M | -15.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.12M | -8.96M | -13.53M | -10.34M | -15.43M |
| EBIT | -10.16M | -9.58M | -12.60M | -9.32M | -11.10M |
| EBITDA | -10.10M | -9.51M | -12.54M | -9.25M | -10.83M |
| EPS Basic | -0.57 | -0.64 | -2.66 | -2.08 | -3.45 |
| Normalized Basic EPS | -0.35 | -0.40 | -1.66 | -1.30 | -1.80 |
| EPS Diluted | -0.57 | -0.64 | -2.66 | -2.08 | -3.45 |
| Normalized Diluted EPS | -0.35 | -0.40 | -1.66 | -1.30 | -1.80 |
| Average Basic Shares Outstanding | 17.89M | 14.10M | 5.09M | 4.97M | 4.48M |
| Average Diluted Shares Outstanding | 17.89M | 14.10M | 5.09M | 4.97M | 4.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
